Fig. 3

CXCL11 was induced from tumor cells by DOC, but not L-OHP. a Representative immunostainings using anti-CXCL11mAbs in sections from untreated (n = 92) and chemotherapy group (n = 8) patients. Figure panel pairs represents images taken with different zooming options; scale bars, 100 μm. b Statistical analysis of the expression of CXCL11 in tumor tissues detected by IHC. n(total) = 100. **p < 0.0001. c Immunofluorescence staining of EpCAM and CXCL11 show that CXCL11 is mainly expressed in tumor cells (n = 5). Scale bars, 50 μm. (D) CXCL11 levels in lung cancer cells in control group vs DOC (10 ng/ml) or/and L-OHP (20 ng/ml) treated group assessed by RT-PCR. Docetaxel (DOC), but not oxaliplatin (L-OHP), induces upregulation of CXCL11 in vitro. Statistical differences between groups were determined by the Student t test. *p < 0.05; **p < 0.0001; NS, non-significant(P > 0.05). e, f, g, h Dose and time effects of DOC on RNA and protein expression of CXCL11 in A549 and H460 lung cancer-derived cells. Data are given as means ± SEM. Significant differences between each group are indicated by **p < 0.0001 or *p < 0.05. Experiments were independently repeated three times